Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction

Matthias Klingele 1,2,3*, Theresa Stadler 1, Danilo Fliser 1, Timo Speer 1, Heinrich V. Groesdonk 4 and Alexander Raddatz 4

Abstract

Background: As of 2009, anticoagulation with citrate was standard practice in continuous renal replacement therapy (CRRT) for critically ill patients at the University Medical Centre of Saarland, Germany. Partial hepatic metabolism of citrate means accumulation may occur during CRRT in critically ill patients with impaired liver function. The aim of this study was to evaluate the actual influence of hepatic function on citrate-associated complications during long-term CRRT.

Methods: In a retrospective study conducted between January 2009 and November 2012, all cases of dialysis therapy performed in the interdisciplinary surgical intensive care unit were analysed. Inclusion criteria were CRRT and regional anticoagulation with citrate, pronounced liver dysfunction, and pathologically reduced indocyanine green plasma disappearance rate (ICG-PDR).

Results: A total of 1339 CRRTs were performed in 69 critically ill patients with liver failure. At admission, the mean Model for End-stage Liver Disease score was 19.2, and the mean ICG-PDR was 9.8%. Eight patients were treated with liver replacement therapy, and 30 underwent transplants. The mortality rate was 40%. The mean duration of dialysis was 19.4 days, and the circuit patency was 62.2 h. Accumulation of citrate was detected indirectly by total serum calcium/ionised serum calcium (tCa/iCa) ratio > 2.4. This was noted in 16 patients (23.2%). Dialysis had not to be discontinued for metabolic disorder or accumulation of citrate in any case. In 26% of cases, metabolic alkalosis occurred with pH > 7.5. Interestingly, no correlation between citrate accumulation and liver function parameters was detected. Moreover, most standard laboratory liver function parameters showed poor predictive capabilities for accumulation of citrate.

Conclusions: Our findings indicate that extra-hepatic metabolism of citrate seems to exist, avoiding in most cases citrate accumulation in critically ill patients despite impaired liver function. Because the citric acid cycle is oxygen-dependent, disturbed microcirculation would result in inadequate citrate metabolism. Raising the tCa/iCa ratio would therefore be an indicator of severity of illness and mortality rather than of liver failure. However, further studies are warranted for confirmation.

Keywords: CRRT, Anticoagulation, Citrate, Critically ill, Liver, Accumulation
Background

Acute renal failure requiring dialysis is a common complication in critically ill patients in intensive care units (ICUs) [1, 2]. In order to perform renal replacement therapy (RRT), adequate anticoagulation is necessary. Heparin is often used for this purpose [2]. However, the bleeding risk may be elevated in critically ill patients, especially in the context of surgery or patients with hepatic impairment. Regional anticoagulation with citrate lowers the risk of bleeding complications and therefore appears to be advantageous in these patients [3]. Admitted citrate is half-eliminated during dialysis. The residual half of citrate does return to the patient. Citrate metabolism is oxygen-dependent via the citric acid cycle and therefore mainly in organs with high amounts of mitochondria, such as the liver, kidney or muscle [4]. In the literature, citrate metabolism is described as being dependent mainly on liver function [5, 6]. Thus, regional anticoagulation with citrate is considered critical in cases of liver dysfunction with respect to the potential risk of citrate accumulation resulting in metabolic disorders, including shifts in calcium balance [6]. Because of these potential side effects, regional anticoagulation with citrate is often avoided in patients with hepatic insufficiency and mostly excluded in studies investigating regional anticoagulation with citrate [7]. To this day, there is still little knowledge about the actual incidence of citrate-associated complications in patients with impaired liver function. Moreover, the existing rare studies describe only short periods of dialysis [8, 9]. Information about continuous renal replacement therapy (CRRT) of longer duration with citrate anticoagulation in critically ill patients with hepatic insufficiency is not available.

This study had three aims: to evaluate the proportion of critically ill patients with severe hepatic insufficiency developing citrate-associated complications during CRRT, to investigate the actual influence of hepatic impairment and duration of CRRT on the development of these citrate-associated complications, and finally to identify predicting factors for citrate-associated complications in critically ill patients with impaired liver function.

Methods

Study cohort

Since January 2009, regional anticoagulation with citrate is routinely used for RRT in all ICUs at the Saarland University Medical Centre. From that time until November 2012, all dialysis cases in the interdisciplinary surgical ICU were analysed. The ethics committee of the medical association evaluated this retrospective study of anonymised data and voted that no ethical approval or consent to participate was needed (ethics vote of the Ethik-Kommission der Aerztekammer des Saarlandes [211/11]).
CVVHD was the only renal replacement modality used. All CRRTs were started according to our standard protocol: Initial blood flow was 100 ml/minute, dialysate flow was 2000 ml/h, citrate solution was infused pre-filter at an initial rate of 4.0 mmol/L blood, and calcium was substituted with 1.7 mmol/L dialysate. In patients with a body weight > 80 kg, flow rates of blood and dialysate were likewise increased as target dialysis dose was > 25 ml/kg/h.

In case of accumulation of citrate, in a first step, dialysate flow was increased by 20–25%. In a second step, blood flow was reduced by 10–20%, if possible with respect to the body weight (minimal blood flow, 1 ml/minute/kg body weight) and target dialysis dose. The last step for correction was a further increase in dialysate flow.

The Molecular Adsorbents Recirculation System (MARS; Baxter, Unterschleißheim, Germany) is an extracorporeal liver dialysis system. It is a further development of albumin dialysis. The first step consists of albumin dialysis of the patient’s blood, whereby toxins are bound to the albumin in the dialysate circuit. In a second step, the albumin-containing dialysate is regenerated for recirculation. For this purpose, albumin-bound toxins are eliminated using an adsorber and by a second dialysis circuit.

In three of eight patients receiving liver replacement therapy, standard CVVHD with RCA was discontinued for the duration of MARS therapy. Furthermore, during MARS therapy, a different dialysis machine was used for liver dialysis (PRISMAFLEX system; Baxter). In addition, heparin was used for anticoagulation of the extracorporeal circuit according to the operating manual of the PRISMAFLEX system used.

Metabolic complications of anticoagulation with citrate

For anticoagulation with citrate we used trisodium citrate (sodium citrate 4%; Fresenius Kabi, Bad Homburg, Germany). Because this contains an increased supply of sodium, we used multiBic (Fresenius Medical Care), a dialysate solution with a reduced degree of sodium, to avoid hypernatremia.

Accumulation of citrate and metabolic alkalosis are the main metabolic disorders described in the context of anticoagulation with citrate. Increased citrate plasma levels were detected by calculating the total tCa to iCa ratio (tCa/iCa) as described by Hetzel and colleagues [14]. A tCa/iCa ratio > 2.4 was considered a sign of accumulation of citrate.

The metabolism of 1 mol of citrate results in 3 mol of bicarbonate (HCO₃⁻). Therefore, we used dialysate solutions with reduced HCO₃⁻ content of 20 mmol/L (multiBic) to avoid development of metabolic alkalosis. Serum level of HCO₃⁻, base excess, respiratory status (blood gas analysis) and pH value were determined at the same time points as iCa, at least four times per day. A blood pH value > 7.5 was considered as alkalosis.

Statistical analysis

Continuous variables are expressed as the mean ± SD. Categorical variables are given as relative and absolute frequencies unless otherwise stated. The association between continuous variables was assessed by Spearman’s rank correlation testing.

To assess the influence of the laboratory variables on the development of accumulation of citrate or alkalosis, logistic and linear regression models were used. None of these complications was used as the reference category in the logistic regression. The predictive value of laboratory markers of liver function on the development of accumulation of citrate or alkalosis was assessed using ROC analysis. Statistical analysis was carried out using IBM SPSS version 20 software (IBM, Armonk, NY, USA).

Results

Between January 2009 and November 2012, a total of 378 patients underwent CRRT during the study period. Of these, 87 patients had acute or chronic liver dysfunction. Because ICG-PDR was not determined systematically, 69 patients were eligible for inclusion in this analysis (as shown in Fig. 1), resulting in a total of 1339 dialysis days of CRRT. The mean duration of CRRT was 19.4 days (SD, ±22.9; range, 1–105) (Table 1).

Most patients had pre-existing liver disease with a mean bilirubin at admission of 7.1 (SD, ±10.4; range, 0.2–41.6), mean ICG-PDR < 10% and mean Model for End-stage Liver Disease (MELD) score of 19.7. During the dialysis period, the average maximum serum level of bilirubin was 15.6 ± 11.4 mg/dl. Liver replacement therapy was performed in eight patients. Thirty patients received liver transplants. Because the aim of this study was to investigate the influence of liver function on the metabolism of citrate during long-term CRRT, the main focus was liver function at the beginning and during the course of dialysis, as shown in Table 2.

At admission, most patients showed impaired renal function, and three patients were on chronic dialysis before admission (Table 2). The indications for dialysis were mainly hypervolaemia (46.4%), uraemia (43.5%) or hyperkalaemia (5.8%). The mean dialysis period was 19.4 days (SD, ±22.9).

Anticoagulation with citrate

Regional anticoagulation with citrate was used in 99.1% of all 1339 CRRTs during the study period. All patients started as described in the “Methods” section with standard flow rates. In 40.6% of all patients and 48.5% of all dialysis performed, exclusively standard flow rates of blood and dialysate were applied during the whole duration of CRRT.
without a need for change owing to metabolic disorders. In three of eight patients receiving MARS for liver replacement therapy, anticoagulation was performed with heparin and not with citrate during this treatment period.

The effective mean blood flow was 96 ml/minute (SD, ±9; range, 80–138), and the mean dialysate flow was 2188 ml/h (SD, ±452; range, 1200–3600), resulting in an effective dialysis dose of 28.9 ml/h/kg. Sufficient anticoagulation was achieved with a mean dose of citrate of 4.0 mmol/L blood (SD, ±0.3; range, 3.4–4.7), resulting in a mean iCa of 0.30 mmol/L (SD, ±0.03; range, 0.12–0.38) in the extracorporeal circuit. The effectiveness of anticoagulation yielded a mean longevity of circuit filters of 62.2 h (SD, ±11.2; range, 24–72). To restore physiological serum levels of calcium, mean calcium substitution of 1.6 mmol/L dialysate (SD, ±0.3; range, 0.6–2.2) was given.

### Table 1

| Parameters                        | Results          |
|----------------------------------|------------------|
| Age, years                       | 69.1 ± 12.4      |
| Male sex, n (%)                  | 47 (68.1)        |
| BMI, kg/m²                       | 26.5 ± 4.6       |
| Pre-existing liver disease       |                  |
| Cirrhosis, n (%)                 | 42 (60.9)        |
| Hepatitis B or C, n (%)          | 10 (14.5)        |
| Alcoholic cirrhosis, n (%)       | 20 (29)          |
| Hepatocellular carcinoma, n (%)  | 9 (13)           |
| Others, n (%)                    | 22 (31.9)        |
| MELD score at admission          | 19.7 ± 9.6       |
| Severity of illness              |                  |
| Maximum SAPS II score            | 56.2 ± 13.6      |
| Maximum TISS score               | 24.2 ± 8.9       |
| Sepsis during dialysis period, n | 29 (42)          |
| Mechanical ventilation during ICU| 57 (82.6)        |
| Outcome                          |                  |
| Duration of ventilation, h       | 425.5 ± 507.8    |
| Length of stay in hospital, days | 62.9 ± 64.9      |
| Length of stay in ICU, days      | 30.4 ± 31.8      |
| Death, n (%)                     | 40 (58.0)        |

### Table 2

| Parameters                        | At start of CRRT | During dialysis period |
|----------------------------------|------------------|------------------------|
| Creatinine, mg/dl                | 2.7 ± 1.3        |                        |
| eGFR, CKD-EPI                    | 24.7 ml/minute   |                        |
| Cystatin C, mg/dl                | 3.2 ± 1.1        |                        |
| GFR, cystatin C                  | 17.7 ml/minute   |                        |
| Bilirubin, mg/dl                 | 9.5 ± 10.6       | 7.9 ± 6.8               |
| Albumin, g/L                     | 24.7 ± 7.0       | 250 ± 4.1              |
| Cholinesterase, ×1000 IE/L       | 2.8 ± 1.7        | 2.6 ± 1.2              |
| ICG-PDR                          | 7.6 ± 5.8        | 9.9 ± 6.3              |
| MELD score                       | 29.8 ± 5.1       |                        |

Metabolic disorder due to anticoagulation with citrate
The occurrence of metabolic complications in this study compared with what would have been expected in patients with impaired liver function undergoing CRRT with RCA is shown in Fig. 2. In 16 patients (23.2%), a ratio of tCa/iCa > 2.4 occurred during CRRT, indicating accumulation of citrate. Mean tCa during the dialysis period was 2.54 ± 0.17 mmol/L. In nine patients, tCa was > 2.7 mmol/L. The highest serum calcium level of tCa measured was 3.7 mmol/L in one patient at 1 day. At any time clinical complications occurred due to hyper- or hypocalciemia. Hypercalcaemia or accumulation of citrate did not require that RCA be stopped in any patient.

Mean HCO₃⁻ was 25.8 ± 4.4 mmol/L during the dialysis period. Metabolic alkalosis occurred in 17 patients (24.6%). Maximal HCO₃⁻ ranged from 19 to 46 mmol/L, accompanied by a mean base excess of 7.7. Adequate modification of CRRT resolved hypercalcaemia or alkalosis.

Factors influencing accumulation of citrate
Comparing the 16 patients showing signs of citrate accumulation with the remaining 53 patients, we found...
that MELD score at the start of dialysis was higher (33.1 ± 4.2 versus 28.8 ± 5.0; \( p = 0.001 \)), Quick value was lower (41.2 ± 23.6 versus 57.1 ± 19.3; \( p = 0.004 \)), duration of dialysis was shorter (11.6 ± 8.6 versus 22.1 ± 26.3; \( p = 0.014 \)) and dose of citrate per litre of blood was higher (4.2 ± 0.6 versus 4.0 ± 0.6; \( p = 0.025 \)). MARS for liver replacement therapy had no impact on accumulation of citrate, as shown in Table 3.

In correlation analysis only MELD score and prothrombin time (Quick value) at the start of dialysis showed a weak correlation (0.303 and −0.387, respectively; \( p = 0.001 \)). In a binary logistic regression model only prothrombin time showed a small impact on the accumulation of citrate. A reduction of 1% in Quick value resulted in an elevation of 0.004 of the tCa/iCa ratio. In ROC analysis the predictive capacity of hepatic parameters (bilirubin, CHE, prothrombin time [Quick value] and ICG-PDR), the dose of citrate and the ICU length of stay for the accumulation of citrate were tested. The resulting AUCs were 0.253 to 0.662, respectively.

**Factors influencing development of alkalosis**
Comparing the 17 patients showing signs of alkalosis with the remaining 52 patients, the Quick value was higher (74.0 ± 11.7 versus 56.4 ± 18.8; \( p = 0.000 \)), the ICG-PDR was higher (13.4 ± 5.6 versus 9.0 ± 6.2; \( p = 0.029 \)), the dose of citrate per litre of blood was lower (3.8 ± 0.2 versus 4.1 ± 0.3; \( p = 0.000 \)), the flow of dialysate was lower (1935 ± 267 versus 2270 ± 470 ml/h; \( p = 0.001 \)) and mortality was lower (35.3% versus 65.4%; \( p = 0.029 \)).

In correlation analysis ICG-PDR and prothrombin time (Quick value) showed a weak correlation with the development of alkalosis (0.348 and 0.427; \( p = 0.029 \) and 0.000, respectively). In a binary logistic regression model only prothrombin time (Quick value) and ICG-PDR showed a weak impact on the development of alkalosis (0.072 and −0.003, respectively). In ROC analysis the predictive capacity of hepatic parameters (bilirubin, CHE, prothrombin time [Quick value] and ICG-PDR) for the development of alkalosis was tested. Only prothrombin time and ICG-PCR showed AUCs above 0.70 (0.785 and 0.736, respectively).

**Discussion**
In this retrospective evaluation, we demonstrate that in critically ill patients with severe hepatic dysfunction, regional anticoagulation with citrate for CRRT is possible, even for long-term dialysis. Although patients showed pronounced impaired liver function, citrate accumulation occurred in only one of four patients and was far less dramatic than expected.
Under physiological conditions, citrate is metabolised by the liver and to a lesser extent by the skeletal muscle [5]. Therefore, RCA is considered as contraindicated in cases of impaired liver function resulting in accumulation of citrate [6, 15–18]. Increased citrate plasma levels are indirectly detected, as described by Hetzel and colleagues [14], through a increasing ratio of total serum calcium (tCa/iCa). The limit of this ratio varies in the literature from 2.1 to ≥ 2.5 [19–21]. Under physiological conditions, tCa ranges from 2.2 to 2.6 mmol/L and iCa ranges from 0.9 to 1.20 mmol/L. The resulting ratio (tCa/iCa) ranges from 1.8 to 2.4. Thus, a tCa/iCa ratio > 2.4 was considered a sign of accumulation of citrate. This threshold was also previously chosen by Link and colleagues [21]. Although all patients included showed pronounced impaired liver function, in almost half of these patients any aspect of metabolic or electrolyte disturbance occurred, and only one of four had signs of citrate accumulation. Furthermore, slight changes in the dialysate and blood flows mostly allowed correction of looming signs of metabolic disorders. These results are in contrast to the conventional wisdom in the literature. However, there is anecdotal evidence that the use of citrate in patients with impaired liver function would be possible [3, 22, 23]. Of note, some studies have reported RCA after liver transplant [8, 24]. However, liver function normally improves after transplant. Furthermore, the described mean dialysis periods were quite short at 5–8 days [8, 24].

In assessing metabolic complications of citrate anticoagulation, in particular the duration of dialysis is of central importance because in prolonged CRRT high cumulative doses of citrate are administered. However, in the literature, only short dialysis periods are described [3, 8, 23–26]. The recently published liver citrate anticoagulation threshold (L-CAT) trial convincingly showed the safety of CRRT-RCA in patients with severely impaired liver function [9]. Of note, the reported observation period included the first 72 h of CRRT-RCA treatment. In contrast, we report the whole duration of CRRT-RCA; the mean duration of the dialysis period was 19 days, resulting in high cumulative doses of citrate.

Taken together, hepatic function seems not to be exclusively or predominantly responsible for citrate metabolism. We therefore hypothesise that in critically ill patients with impaired liver function a part of citrate metabolism is shifted into muscle cells or any other cells. This also would explain why the duration of dialysis with consecutive high cumulative doses of citrate does not result in accumulation and metabolic disorder.

### Table 3

| Parameter                                           | Accumulation of citrate; tCa/iCa ratio > 2.4 | No accumulation of citrate; tCa/iCa ratio ≤ 2.4 | p Value |
|-----------------------------------------------------|---------------------------------------------|-----------------------------------------------|---------|
| No. of patients                                     | 16                                          | 53                                            |         |
| Age, years                                          | 57.4 ± 14.0                                 | 59.6 ± 11.9                                   | n.s.    |
| MELD score                                          | 33.1 ± 4.2                                  | 28.8 ± 5.0                                    | 0.001   |
| Prothrombin time, Quick value (%)                   | 41.2 ± 23.6                                 | 57.1 ± 19.3                                   | 0.004   |
| Bilirubin, mg/dl                                    | 8.3 ± 11.1                                  | 8.7 ± 11.9                                    | n.s.    |
| ICG-PDR                                             | 7.4 ± 5.5                                   | 10.7 ± 6.4                                    | n.s.    |
| Duration of CRRT, days                              | 11.6 ± 8.6                                  | 22.1 ± 26.3                                   | 0.014   |
| Mean flow of dialysate, ml/h                         | 2234.1 ± 501.9                              | 2173.7 ± 437.8                                | n.s.    |
| Effective dialysis dose, ml/kg/h                     | 28.8 ± 8.5                                  | 28.9 ± 8.6                                    | n.s.    |
| Mean dose of citrate, mmol/L blood                  | 4.2 ± 2.6                                   | 4.0 ± 2.6                                     | 0.025   |
| Mean Ca\(^2+\) substitution, mmol/L dialysate       | 1.66 ± 0.15                                 | 1.55 ± 0.30                                   | 0.038   |
| Total Ca\(^2+\), mmol/L                            | 2.67 ± 0.17                                 | 2.47 ± 0.15                                   | 0.000   |
| iCa post–filter, mmol/L                             | 0.32 ± 0.02                                 | 0.29 ± 0.05                                   | 0.001   |
| iCa in patient, mmol/L                              | 1.07 ± 0.06                                 | 1.14 ± 0.09                                   | 0.000   |
| Death, n (%)                                        | 11 (68.8%)                                  | 29 (54.7%)                                    | n.s.    |
| Vasopressor support, % of CRRT duration             | 65.8 ± 39.7                                 | 55.2 ± 32.8                                   | n.s.    |
| Maximal SAPS II score                               | 56.2 ± 14.4                                 | 56.2 ± 13.5                                   | n.s.    |
| Stay in ICU, days                                   | 14.9 ± 11.6                                 | 35.1 ± 34.1                                   | 0.001   |

*Abbreviations: CRRT Continuous renal replacement therapy, iCa Ionised serum calcium, ICG-PDR Indocyanine green plasma disappearance rate, ICU Intensive care unit, MELD Model for End-stage Liver Disease, n.s. Not significant, SAPS II Simplified Acute Physiology Score II, tCa/iCa Total serum calcium/ionised serum calcium
Results are shown as mean ± SD*
Theoretically, smaller doses of citrate would also reduce the cumulative dose during long-term dialysis and RCA with citrate. However, adequate anticoagulation is an essential requirement to ensure the patency of the dialysis circuit. Therefore, mean circuit lifespan is an indirect indicator of the effectiveness of anticoagulation. RCA circuit lifespans up to 48 h and more have been reported [14, 25, 27, 28]. In our study mean circuit patency was 62.2 h, confirming adequate anticoagulation over time. Thus, despite high cumulative doses of citrate during a mean dialysis period of 19 days, citrate accumulation occurred in only 23% of patients.

Metabolism of administrated citrate can induce metabolic alkalosis. Under physiological conditions citrate is cleared by the citric acid cycle (tricarboxylic acid cycle), resulting in 3 mmol of NaHCO$_3$ per 1 mmol of trisodium citrate [29]. In the literature the incidence of alkalosis during RCA with citrate is reported in 23–55% of patients [30, 31]. Different citrate formulations and HCO$_3$ concentrations of the dialysate or replacement solutions may partially explain these different incidences of alkalosis. However, the occurrence of alkalosis also depends on rapid metabolism of citrate. This is thought to be dependent mainly on liver function [8]. In one-fourth of patients in our study, metabolic alkalosis occurred, in line with other reported incidences. Of note, in contrast to studies reporting on alkalosis, all of our included patients had severely impaired liver function. We interpret this fact as a further indication of our former described hypothesis that an adequate citrate metabolism must be possible also outside the liver.

In the literature, citrate metabolism is primarily associated with hepatic function. Therefore, baseline liver function parameters should be predictive regarding citrate accumulation during CRRT with RCA. However, most standard laboratory liver function parameters showed poor predictive capabilities [3, 6, 26]. This raises the question whether impaired hepatic function is really the main reason for accumulation of citrate. This poor prediction of citrate accumulation by parameters of liver function appears to be a further indication that an effective extrahepatic metabolism of citrate seems to exist. Our results are consistent with the recently published study by Slowinski and colleagues [9]. However, the reported observation period of CRRT was 3 days (first 72 h of CRRT). Thus, comparability with our study is limited.

Because in all cells citrate can be metabolised within the Cori cycle (tricarboxylic acid cycle), we hypothesise that an impaired perfusion on the microvascular and cellular levels is critical to the metabolism of citrate. This hypothesis is supported by the observations of Schultheiss and colleagues, who described a baseline serum lactate level $\geq$3.4 mmol/L as a predictor of citrate accumulation [3], and of Link and colleagues, who showed that in patients with signs of citrate accumulation, mean arterial blood pressure was lower and dose of norepinephrine was higher than in those without citrate accumulation [21]. This hypothesis has also been suggested by recent studies, some of them pointing at hyperlactataemia [32] or, more specifically, at lactate kinetics during treatment [33] as a useful predictor for citrate accumulation. Disturbed microvascular circulation could also cause altered hepatic function, resulting in an association of impaired liver function and citrate accumulation. This hypothesis would also explain why in the literature inconsistent results exist concerning liver function and accumulation of citrate. Moreover, a correlation was described between the tCa/iCa ratio and hepatic clearance measured by the ICG-PDR and multi-organ dysfunction measured by SAPS II score during CRRT-RCA [21]. On the basis of our data, we cannot prove the hypothesis that shock and disturbed microcirculation are mainly responsible for disturbed citrate metabolism. However, patients developing citrate accumulation had a higher need for vasopressor therapy and showed lower ICG-PDR. In addition, reduced ICG-PDR is not only a sign of impaired liver function but also was recently shown to be correlated with impaired hepatic perfusion [34].

**Limitations**

The retrospective design of this study limits the meaningfulness of our hypothesis. The number of included patients is quite small. This could result in bias despite the long dialysis period and the high number of dialysis. Furthermore, ICG-PDR is not available in all centres and was not performed in all patients in our centre. Because the duration of MARS results in discontinuity of the load with citrate, this may have an impact on metabolic complications. Not all laboratory data are available in all patients at all time points desired for this evaluation.

**Conclusions**

Our findings may serve to somewhat dispel the notions that RCA is contraindicated in critically ill patients with impaired liver function. Citrate metabolism seems not to be restricted to the liver. Therefore, liver failure in patients treated by CRRT with RCA does not automatically result in accumulation of citrate. However, caution and close monitoring of metabolic disorders are needed because wrong management of RCA can result in serious adverse effects in critically ill patients with impaired liver function. Further studies are warranted to confirm our findings.

**Abbreviations**

BMI: Body mass index; CHE: Cholinesterase; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration equation; CRRT: Continuous renal replacement therapy; CRRT-RCA: Continuous renal replacement therapy with regional
citrate anticoagulation; CVVHD: Continuous venovenous haemodialysis; eGFR: Estimated glomerular filtration rate; HCO₃⁻: Bicarbonate; ICG-PDR: Indocyanine green plasma disappearance rate; ICU: Intensive care unit; L-CAT: Liver citrate anticoagulation threshold; MARS: Molecular Adsorbents Recirculation System; MELD: Model for End-stage Liver Disease; n.s.: Not significant; RCA: Regional citrate anticoagulation; RRT: Renal replacement therapy; SAPS II: Simplified Acute Physiology Score II; tCa/iCa: Total serum calcium/ionised serum calcium; TISS: Therapeutic Intervention Scoring System

Acknowledgements
None

Funding
No financial support was received for this study.

Availability of data and materials
Not applicable in this retrospective evaluation of clinical data.

Authors’ contributions
MK designed the study. MK, Tsp, DF and HVG and AR were responsible for medical care. Tst and MK wrote the manuscript. All authors discussed the results and implications and commented on the manuscript at all stages. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable, see the Methods section of the main text.

Consent for publication
Not applicable, see the Methods section of the main text.

Competing interests
MK received speaker fees from Baxter, Fresenius Medical Care and Cytosorbents, DF received honoraria from Fresenius Medical Care. The other authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Internal Medicine – Nephrology and Hypertension, Saarland University Medical Centre, Homburg/Saar, Germany. 2Departments of Nephrology and Internal Medicine, Hochtuaunus-Kliniken, Zeppelinstrasse 20, D-61352 Bad Homburg, Germany. 3Departments of Nephrology and Internal Medicine, Hochtuaunus-Kliniken, 61250 Usingen, Germany. 4Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Medical Centre, Homburg/Saar, Germany.

Received: 24 July 2017 Accepted: 23 October 2017
Published online: 29 November 2017

References
1. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008;36(4 Suppl):S146–S151.
2. Ostermann M, Dickie H, Tovey L, Treacher D. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit Care. 2010;14(4):419.
3. Schultheiss C, Saugel B, Heger J, Haas J, Trauner M. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. Liver Int. 2009;29(10):1516–20.
4. Calazis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron. 2001;89(3):233–6.
5. Hetzel GR, Taskaya I, Suck C, Herrnreiter M, Grabensee B, Schmutz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis. 2006;48(5):806–11.
6. Apner R, Schwarzenhofer M, Derfler K, Zauer C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr. 1997;109(9):123–7.
7. Leung AK, Shum HP, Chan KC, Chan SC, Lai KY, Yan WW. A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients. Crit Care Res Pract. 2013;2013:349512.
8. Slater FH, Treckmann JW, Geis A, Losch C, Witteke O, Carbayo A, Herget-Rosenthal S, Kribben A, Paul A, Feldkamp T. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol Dial Transplant. 2012;27(4):1651–7.
9. Slowinski T, Morgasa S, Joannidis M, Henneberg T, Stocker R, Helset E, Andersson K, Wehner M, Kozik-Jaromin J, Brett S, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodiagnosis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care. 2015;19:349.
27. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30(2):260–5.

28. Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blows H, Baker C, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005;20(7):1416–21.

29. Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus. 2009;2(6):439–47.

30. Morige A, Scholte C, Voss G, Hase M, Vargas-Hein O, Krausch D, Meber C, Rosseau S, Zuckermann-Becker H, Neumayer HH. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract. 2004;97(4):c131–6.

31. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38(5):976–81.

32. Tan JN, Haroon SW, Mukhopadhyay A, Lau T, Murali TM, Phua J, Tan ZY, Lee N, Chua HR. Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy. J Intensive Care Med. 2017. doi:10.1177/0885066617701068.

33. Khadjznyov D, Dahlinger A, Schelter C, Peters H, Kindgen-Milles D, Budde K, Lehner L, Halleck F, Staeck O, Slowinski T. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med. 2017;45(9):e941–6.

34. Malbrain ML, Vlaeni D, Kortgen A, De Laet I, Dits H, Van Regenmortel N, Schoonheydt K, Bauer M. Relationship between intra-abdominal pressure and indocyanine green plasma disappearance rate: hepatic perfusion may be impaired in critically ill patients with intra-abdominal hypertension. Ann Intensive Care. 2012;2 Suppl 1:519.